Genexine announced that its partner, I-Mab, recently completed patient enrollment in a phase 3 clinical trial of its proprietary long-acting growth hormone, eftansomatropin alfa, also known as GX-H9/TJ101, in China, taking it one step closer to commercialization in a key market. Eftansomatropin alfa (GX-H9/TJ101) was discovered by Genexine and is being co-developed by Genexine and Handok for the potential treatment of pediatric and adult growth hormone deficiency. The phase 3 clinical trial (TALLER) being conducted in China by I-Mab, is a multi-center, randomized, open-label, active-controlled clinical study enrolling 168 patients with pediatric growth hormone deficiency (PGHD).

The study is evaluating the efficacy, safety, and pharmacokinetics (PK) of eftansomatropin alfa in PGHD, as compared to Norditropin®, a daily rhGH marketed in China.